Home / 2014 / October (page 4)

Monthly Archives: October 2014

The Impact of Mediterranean Diets on Metabolic Syndrome

A supplemented Mediterranean diet can lead to metabolic syndrome reversal…. Metabolic syndrome is characterized by risk factors that increase an individual’s chances for cardiovascular disease. These risk factors include obesity, hypertension, high cholesterol and uncontrolled blood glucose. In addition to cardiovascular disease, those with metabolic syndrome are at increased risk …

Read More »

Grapefruit Juice May Affect Insulin Resistance

Drinking grapefruit juice daily can lead to weight loss and help control blood glucose… Grapefruit juice is considered to be high in nutrients while remaining relatively low in calories when compared to other fruit juices. These diets often rely on daily low calorie commitment, which calls into question the true …

Read More »

Blocking a Genetic Variant Associated with Type 2 Diabetes May Improve Insulin Secretion

Yohimbine, a α2A-adrenergic receptor agonist, showed a 29% increase in insulin secretion in patients with type 2 diabetes related to the genetic variation… The feasibility of exploiting genomic information for individualized treatment of polygenic diseases remains uncertain. A genetic variant in ADRA2A, which encodes the α2A-adrenergic receptor (α2AAR), was recently associated with type …

Read More »

Diabetes Patients Have a Poor Response to Stress

Type 2 diabetes patients exhibited a weak ability to regulate blood pressure, cholesterol and heart rate when they experienced stress, a new study showed. Researchers also noted increased depressive and hostile symptoms in these patients. The researchers looked at the biological systems of 140 patients with type 2 diabetes and …

Read More »

High-intensity Statin Treatment Improves Diabetic Coronary Atherosclerosis

Cleveland Clinic researchers found that high-intensity statin treatment was associated with coronary atheroma regression in patients with or without diabetes, suggesting the therapy may halt the progression of diabetic coronary atherosclerosis. Coronary atheroma volume was measured using serial intravascular ultrasound in patients treated with rosuvastatin 40 mg or atorvastatin 80 …

Read More »

Trulicity Once-Weekly GLP-1 Shipping Now

Trulicity Once-Weekly GLP-1 Shipping Now  Eli Lilly and Company announced that Trulicity, a glucagon-like peptide-1 receptor agonist (GLP-1 RA) with once-weekly dosing in the Trulicity pen, was approved by the FDA on September 18, 2014, and is shipping to distributors now.

Read More »